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Abstract S100 proteins are small, calcium-binding proteins
whose genes are localized in a cluster on human chromosome
1. Through their ability to interact with various protein partners
in a calcium-dependent manner, the S100 proteins exert their
influence on many vital cellular processes such as cell cycle,
cytoskeleton activity and cell motility, differentiation, etc. The
characteristic feature of S100 proteins is their cell-specific
expression,whichisfrequentlyup-ordownregulatedinvarious
pathological states, including cancer. Changes in S100 protein
expression are usually characteristic for a given type of cancer
and are therefore often considered as markers of a malignant
state. Recent results indicate that changes in S100 protein
expression may depend on the extent of DNA methylation in
the S100 gene regulatory regions. The range of epigenetic
changes occurring within the S100 gene cluster has not been
defined. This article reviews published data on the involvement
of epigenetic factors in the control of S100 protein expression
in development and cancer.
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The S100 proteins
The S100 protein family consists of small (10–12 kDa),
acidic calcium-binding proteins that form noncovalent
homo- or heterodimers. Each S100 protein monomer
contains two EF-hand structures, specialized in binding
calcium ions, which are linked by a central hinge region of
variable length. The affinities of S100 proteins for Ca
2+ are
within the micromolar range, implying that they may bind
calcium ions under physiological conditions in activated
cells. For most S100 proteins, the binding of calcium ions
results in a pronounced conformational change exposing
regions engaged in protein–protein interactions. Many of
the S100 proteins also bind Cu
2+ and Zn
2+ ions with high
affinity, but the binding sites are poorly defined (for review,
see Donato 2001; Marenholz et al. 2004; Santamaria-Kisiel
et al. 2006).
Devoid of any intrinsic enzymatic activity, the S100
proteins can nonetheless exert their influence on many
intracellular processes through interactions with diverse
partners. Binding of an S100 protein can affect the target
protein conformation, activity, ability to interact with other
proteins or can interfere with its posttranslational modifi-
cations, for example, phosphorylation. Since the list of
S100 protein targets is rather impressive, calcium-induced
interactions involving S100 proteins may entail a wide
spectrum of physiological consequences, including changes
in cytoskeleton dynamics, cell mobility and adhesion, cell
cycle, differentiation, etc. (Santamaria-Kisiel et al. 2006).
Extracellularly, these proteins act as trophic and chemotactic
factors and RAGE receptor ligands (Perera et al. 2010;
Leclerc et al. 2009). Multiple experimental data strongly
suggest that, in spite of a high structural similarity, subtle
differences in calcium-binding affinities and in the amino
acid sequence, especially in the C-termini, together with
differences in expression profiles, result in specific non-
redundant functions of the S100 proteins.
Phylogenetically, these proteins appear to be a young
group present only in vertebrates (Shang et al. 2008).
Interestingly, most of the genes coding for S100 proteins
are localized in a cluster on human chromosome 1q21,
mouse chromosome 3f2 (Schafer et al. 1995; Ridinger et al.
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2004). The clustered organization of genes gave rise to the
systematization of S100 proteins and unification of their
nomenclature; proteins coded by genes located within the
cluster on chromosome 1 in man were assigned as S100A
proteins with numbers, e.g., S100A1 and S100A2, reflect-
ing the position of the gene in the cluster (Schafer et al.
1995; Marenholz et al. 2006; Fig. 1). In man, the remaining
S100 genes are located on chromosomes 21q22 (S100B),
Xp22 (S100G), 4p16 (S100P), and 5q14 (S100Z). With few
exceptions, the S100 genes consist of three exons and two
introns. The first exon is not translated, and the remaining
two encode one EF-hand structure each.
Although the genes of S100 proteins are located in a
cluster, there is no evidence that their expression is by any
means synchronized either in a cell-specific or develop-
mental manner. Quite the opposite—there are many reports
showing that in a given cell type, a certain S100 protein
may be abundant while the one encoded by a neighboring
gene is expressed at a low level or absent. Therefore,
studies which compared the expression of a panel of S100
proteins in a given cell type or tissue, or in a set of normal
versus cancerous tissues, led to the conclusion that, despite
structural similarities and clustered genes, each S100
protein has a very specific expression pattern (Pedrocchi
et al. 1994; Elder and Zhao 2002; Cross et al. 2005).
Another interesting feature of S100 proteins is that
expression of an individual protein may be completely
different between cell lines, even those derived from related
sources. Attempts aimed at identifying cell-specific tran-
scription factors that would underlie this phenomenon have
failed because exogenously introduced promoter constructs
appeared to be equally active in cells differing in
endogenous expression of a given S100 protein (Tulchinsky
et al. 1992; Wicki et al. 1997; Lesniak et al. 2000). These
observations turned the attention to epigenetic factors that
could be involved in the control of S100 protein expression.
Epigenetic features of the S100 gene cluster
First indications that epigenetic mechanisms may be
important in the regulation of S100 protein expression
came mainly from the observations that in non-expressing
cells, the synthesis of a given S100 protein could be
reactivated in response to DNA methyltransferase inhibitors
such as 5-aza-cytidine. For example, reexpression of
S100A4 was described for lymphoma cells (Tulchinsky et
al. 1995) following an earlier observation of differential
sensitivity of the S100A4 gene 5′ flanking region to HpaII
digestion in S100A4 expressing and non-expressing mouse
adenosarcoma cell lines (Tulchinsky et al. 1992). Likewise,
S100A2 reexpression upon 5-aza-cytidine treatment was
observed in tumor-derived mammary epithelial cells (Lee
et al. 1992) and that of S100A6 in non-expressing HepG-2
cells (Leśniak et al. 2000). These proteins as well as
S100A3, S100A10, S10011, and S100P could be detected
in various medulloblastoma cell lines after DNA demethy-
lation (Lindsey et al. 2007).
Fig. 1 Localization of CpG islands (bars) within the S100 gene cluster
on human chromosome 1q21. The CpG Island Searcher and CpGplot
programs were used. Only islands fulfilling the following criteria: CG
content >55%, expected CpG/observed CpG >0.65, length >200 bp and
identified by both programs are shown. Islands longer than 500 bp are
indicated by thick bars. Positions of the examined regions are given
according to the USCS Genome Browser
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inhibitorsimpliesthatthegenehasbeensilencedbymethylation
of cytosine residues within CpGpairs located,most presumably,
in its regulatory regions (Curradi et al. 2002). Mammalian
genomes are depleted in CpG pairs, except for short DNA
stretches with higher than average CpG density, which are
called CpG islands (Gardiner-Garden and Frommer 1987).
CpG islands often coincide with gene promoters, and their
methylation is associated with repressed chromatin state and
transcription inhibition. Results of the analysis of the S100
gene cluster for the presence of CpG islands are presented in
Fig. 1. CpG islands were identified in 5′ regulatory regions of
S100A2, S100A6, S100A10, and S100A11 genes (Fig. 1,
bars). They cover the proximal promoter, the first non-
translated exon and part of the first intron (S100A6,
S100A10, and S100A11), or the first exon and part of the
first intron (S100A2). In addition to that, the S100A10 and
S100A11 genes have another CpG island in their respective
first introns, which makes them the most CpG-rich S100
genes. A CpG island is also found in the first intron of the
S100A12 gene. CpG islands in the promoters of the S100A6,
S100A10, S100A11 genes and in the first intron of the
S100A11 gene fulfill the more stringent criteria described by
Takai and Jones (2002), i.e., they are longer than 500 bp
(Fig. 1, thick bars). Several CpG islands were found in the
intragenic DNA regions within the S100 gene cluster and at
the 3′ flanking regions of S100A1 and S100A10 genes
(Fig. 1). Examination of the 5-kb vicinity of other S100 genes
did not detect any promoter CpG islands. The S100P and
S100Z genes proved to be CpG island-free, while S100B and
S100G genes have CpG islands in 3′ flanking regions close to
their third exons.
DNA methylation and S100 protein expression in cancer
Many S100 proteins have been reported to change their
expression during cancer progression (for review, see
Sedaghat and Notopoulos 2008; Salama et al. 2008) which
gave rise to speculations about their causative role in
various malignances. The most illustrative example of this
presumption is the fact that S100A4, the level of which is
often increased in metastatic cancers, was named metastasin
(Grigorian et al. 1993) while the S100A2 protein, which is
downregulated in many cancer tissues, is often referred to
as a tumor suppressor protein (Wicki et al. 1997).
Furthermore, S100B, S100A6, and some other S100
proteins were proposed as clinical markers of various
malignances. Evidence has accumulated in recent years
showing that changes in S100 protein expression in cancer
are, in many cases, due to epigenetic mechanisms.
It is now well established that the genome of cancer
cells is largely hypomethylated but that, parallely, some
genes, including these coding for tumor-suppresor proteins,
undergo hypermethylation (Łuczak and Jagodziński 2006).
As described below and summarized in Table 1, the S100
proteins seem to be frequent subjects of this aberrant
methylation status.
The S100A2 gene expression was found to be down-
regulated in breast cancer cells (Lee et al. 1992, Wicki et al.
1997). Accordingly, methylation of several among the 14
CpGs present within the −1227/−201 fragment of the
S100A2 gene promoter was shown, by bisulfite sequencing,
to be increased in breast cancer cell lines and breast cancer
biopsies when compared to normal epithelium (Wicki et al.
1997). There were, however, no changes in the extent of
methylation in the further upstream promoter region
(∼−2,000 bp) and in the first intron (Wicki et al. 1997). On
the other hand, the loss of S100A2 expression in prostate
cancer tissues and cell lines could not be correlated with
DNA methylation in the promoter fragment studied by
Wicki et al. (1997) since the extent of methylation was
similar in S100A2 expressing and non-expressing cells and
tissues (Rehman et al. 2005). Downregulation of S100A2
expression was also observed by immunohistochemistry in
lung cancer tissues (Feng et al. 2001). When studied in non-
small cell lung cancer cell lines, diminished S100A2
expression was shown to correlate with methylation of CpGs
within a 198-bp-long fragment of the first intron. Likewise,
lower level of S100A2 in cell lines derived from lymph node
metastases of head and neck cancer than in the parental non-
metastatic cell line has been correlated with increased
methylation within the intronic region (Zhang et al. 2007).
As mentioned above, the S100A4 protein is often
overexpressed in cancer, and its higher level is thought to
contribute to increased cancer metastasis (Garret et al.
2006). Although the S100A4 gene appears to contain less
than an average number of CpG sites, earlier observations
indicated that its expression could be increased by 5-aza-
cytidine (Chen et al. 1999). Examination of bisulfite
sensitivity of cytosine residues in rat mammary cancer cell
lines exhibiting different levels of S100A4 showed that the
TATA box (−113/+36) and intronic (+135/+312) regions
were differentially methylated while the upstream promoter
region (−1404/−1227) revealed comparable sensitivity to
bisulfite treatment (Chen et al. 1999). Similar results were
obtained for human colon adenocarcinoma cell lines. The
upstream promoter region (∼−800) and the downstream
region (+1124/+1439) were methylated regardless of the
actual S100A4 expression level while three CpG sites
(+35, +386, +777) within the intron were mostly
unmethylated in S100A4 expressing cell lines and
methylated in non-expressing ones (Nakamura et al.
1998). Likewise, a lower methylation level of cytosines at
positions +315, +331, and +386 correlated with high
S100A4 expression in pancreatic cancer cell lines (Rosty
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w i t h i nt h ei n t r o n i cr e g i o nw e r ea l s oo b s e r v e di ne n d o m e -
trial cancer cell lines and tissues. Methylation was
detected in benign endometrium and grade I tumors
expressing low levels of S100A4 but not in grade III
tumors with high S100A4 expression (Xie et al. 2007).
Expression-related hypomethylation of the intron in the
S100A4 gene was also observed in 17% of medulloblastoma
cases, versus normal cerebellum samples, and in 33% of
medulloblastoma cell lines studied (Lindsey et al. 2007). An
opposite situation, i.e., downregulation of S100A4 expres-
sion, was reported for various human epidermal cancers (Li
et al. 2009). In that case, as exemplified by squamous cell
carcinoma sample analysis, four CpG pairs within the gene
intronic region became methylated in the cancerous tissues
when compared with normal epidermis.
Evidence of both epigenetic silencing and induction in
cancer has been obtained for the S100A6 gene. Rehman
et al. (2004) observed S100A6 expression in all of the 66
studied cases of benign epithelium adjacent to prostatic
adenocarcinoma and a complete loss of staining in
adenocarcinomas. Loss of S100A6 expression was also
observed in several prostate cancer cell lines. Subsequent
examination of S100A6 gene promoter methylation in
expressing and non-expressing cells and benign versus
cancerous prostate tissues revealed increased methylation of
cytosine residues within a 267-bp gene fragment covering a
part of the promoter and of the first non-translated exon in
non-expressing cell lines (Rehman et al. 2004) and in 52%
of prostate cancer tissues examined (Rehman et al. 2005).
Methylation of the same gene region was studied in
medulloblastoma cell lines and primary medulloblastomas
following the observation that S100A6 expression was
increased after 5-aza-cytidine treatment (Lindsey et al.
2007). While in cell lines the extent of cytosine methylation
was strictly correlated with the lack of S100A6 expression,
the level of methylation was very low in primary
medulloblastomas. Only five out of 40 studied tumors
showed evidence of increased methylation of the S100A6
gene promoter/first exon when compared to methylation-free
Table 1 Changes in S100 gene methylation and expression in cancer
S100
protein
Cell/tissue S100 protein
expression
Gene region examined Methylation
(cancer vs. control)
Reference
S100A2 Breast cancer cell lines and biopsies ↓ Proximal promoter ↑ Wicki et al. 1997;
Upstream promoter No change
1
st intron No change
Prostate cancer cell lines and tissues ↓ Proximal promoter No change Rehman et al. 2005;
Non-small lung cancer cell lines ↓ 1
st intron ↑ Feng et al. 2001;
Head and neck cancer lymph
metastases
↓ 1
st intron ↑ Zhang et al. 2007;
S100A4 Rat mammary cancer cell lines ↑ 1
st intron, TATA box region ↓ Chen et al. 1999;
Upstream promoter No change
Colon adenocarcinoma cell lines ↑ 1
st intron ↓ Nakamura et al. 1998;
Upstream promoter No change
Downstream region No change
Pancreatic cancer cell lines ↑ 1
st intron ↓ Rosty et al. 2002;
Endometrium grade III tumors and
cell lines
↑ 1
st intron ↓ Xie et al. 2007;
Medulloblastoma tissue and cell lines ↑ 1
st intron ↓ Lindsey et al. 2007;
Epidermal cancer cell lines and
squamous cell carcinoma
↓ 1
st intron ↑ Li et al. 2009
S100A6 Prostate cancer tissue and cell lines ↓ Promoter/1
st exon ↑ Rehman et al. 2005;
Medulloblastoma cell lines ↓ Promoter/1
st exon ↑ Lindsey et al. 2007;
Medulloblastomas ↓ Promoter/1
st exon No change Anderton et al. 2008
Gastric cancer tissue ↑ 1
st intron/2
nd exon ↓ Wang et al. 2010;
S100A10 Primary human pituitary tumors ↓ Proximal promoter ↑ Dudley et al. 2008;
Medulloblastoma tissue and cell lines ↓ Proximal promoter ↑ Lindsey et al. 2007;
Anderton et al. 2008
S100P Primary pancreatic adenocarcinomas ↑ Promoter/1
st exon ↓ Sato et al. 2004;
Prostate cancer cell lines ↑ Promoter/1
st exon ↓ Wang et al. 2007
↑ increase, ↓ decrease
80 Clin Epigenet (2011) 2:77–83normal cerebella. A subsequent study (Anderton et al. 2008)
confirmed that the gene was methylated in medulloblastoma
cell lines but not in 16 primary tumors studied, suggesting
that methylation may concern cultured cells and not to occur
to a great extent in primary tumors. DNA hypomethylation
as the cause of S100A6 overexpression in gastric cancer has
been reported by Wang et al. (2010). A slightly lower
average methylation of four, among five, CpG sites present
in the first intron/second exon region of the S100A6 gene
was detected in 53 gastric cancer tissues examined when
compared to adjacent non-neoplastic mucosa. This lower
methylation rate corresponded to a higher level of acetylated
histone H3 associated with the S100A6 gene promoter
region.
S100A10 expression was found to be diminished due to
methylation in non-expressing primary human pituitary
tumors relative to normal pituitary. Five cytosine residues
in a 146-bp-long fragment of the S100A10 gene promoter
examined (−745/−600) were more often methylated than
the corresponding cytosines in normal tissue (Dudley et al.
2008). Thirteen CpGs in a 252-bp-long promoter fragment
(−652/−400) were also found to be more often methylated
in medulloblastomas (Lindsey et al. 2007; Anderton et al.
2008).
S100P was found to be expressed, and the gene proximal
promoter/first exon region to be hypomethylated, in seven
dissected primary pancreatic adenocarcinomas when compared
to normal pancreatic ductal epithelium in which the S100P
gene was methylated (Sato et al. 2004). Accordingly,
hypomethylation was detected in 30 of 34 xenografts and in
pancreatic cancer cell lines. Lower methylation of the S100P
gene proximal promoter/first exon region was also detected in
prostate cancer cell lines (Wang et al. 2007).
DNA methylation and regulation of developmental
and cell-specific expression of S100 proteins
InadditiontodataconcerningaberrantS100genemethylation
in cancer, there is also increasing evidence that epigenetic
events may accompany the developmental or stimulus-
induced induction/upregulation of S100 protein expression.
Malup et al. (2007) studied methylation of the −455/+131
gene promoter fragment in relation to cell and tissue-specific
expression of S100B in brain astrocytes. Examination of four
CpG sites (−207,−65,+5, +103) revealed a predominant
absence of CpG methylation in the studied region in DNA
clones isolated from total brain when compared to those
isolated from other organs. Another study investigated the
relation between S100B gene promoter methylation and the
developmental stage-dependent expression of S100B in fetal
mouse brain (Namihira et al. 2004). S100B expression was
first observed in the subventricular layer of the telencephalic
cortex of E14.5 mouse brains. Four cytosine residues (−818,
−318, −207, −64), within a 860-bp-long promoter region
studied, were highly methylated in E11.5 neuroepithelial
cells which do not express S100B. Interestingly, methylation
frequency at the −318 CpG site, but not at the remaining
three cytosine residues, was significantly reduced in E14.5
neuroepithelial cells coinciding with the onset of S100B
expression. Demethylation of cytosine at the −318 position
corresponded with a reduced binding of MeCP2 to the
promoter. The authors speculated that the binding of MeCp2
to the methylated −318 cytosine residue inactivated the gene
while its demethylation relieved the inhibition and could be
coupled to fetal brain cell differentiation into the astrocyte
cell lineage (Namihira et al. 2004). Further work showed that
demethylation of cytosine at position −318 in 11.5E neuronal
precursor cells occurred in response to Notch signaling
(NICD overexpression) and prompted the binding of the NFI
transcription factor to a nearby binding site on the S100B
promoter, leading to activation of S100B gene transcription
(Namihira et al. 2009).
Expression of S100A4 due to DNA demethylation
induced as a result of integrin α6β4 signaling has also
been reported (Chen et al. 2009). Five among seven CpGs
within the +208/+662 intronic region studied were found to
be largely methylation-free in MDA-MB-435 cells that
stably expressed integrin α6β4 when compared to control
cells. This demethylation coincided with the binding of the
NFAT5 transcription factor to two sites located within the
studied fragment.
Concluding remarks
All the above data seem to support the thesis that epigenetic
factors play a role in regulating S100 protein expression
both in development, as exemplified by data on S100B, and
during malignant transformation. The latter is certainly true
for cancer cell lines where the differences in DNA
methylation between expressing and non-expressing cells
are most manifested and can be unanimously correlated
with protein expression. A criticism is often raised that
DNA methylation pattern in established cell lines can be
changed in response to culture conditions and does not
reflect the in vivo situation. This criticism does not seem to
hold for the S100 protein genes since with the exception of
the S100A6 gene in medulloblastomas, examination of
cancer tissue specimen confirmed that downregulation of
S100 protein expression was accompanied by DNA
methylation of the respective gene. Less pronounced
differences in the methylation status, when compared to
cell lines, can be attributed to higher heterogeneity of tissue
samples which may contain both expressing and non-
expressing cell types.
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expression) concern the S100 genes independently of the
CpG density in their regulatory regions. It becomes evident
from the literature cited above that both the genes
containing CpG islands (S100A6, S100A10, etc.) as well
as relatively CpG-poor genes (S100A4) can be silenced by
DNA methylation. The concept of DNA methylation
envisages two possible ways by which methylated cytosine
residues may interfere with DNA transcription: (1) they
may abrogate the binding of a transcription factor and/or of
the basal transcriptional machinery and (2) they may attract
methyl-binding proteins, for example MeCP2, that, together
with histone deacetylases and other co-repressors, rebuild
chromatin to a tightly packed, transcriptionally inactive
form (Bird and Wolfe 1999). The former mode implicates
that even a single methylated cytosine residue can seriously
disturb the transcription rate while the other concept would
require that a larger fragment of DNA be methylated to
achievea stableinactivechromatinconformation.Concerning
the first possibility, it was shown, for example, that binding of
the upstream stimulatory factor, USF, to the E-box sequence
in the S100A6 promoter was inhibited in cells in which the
promoterDNAwas methylated(Lesniaketal. 2007). Also, as
noted above, loss of methylation facilitated the binding of
NFI to the S100B gene promoter (Namihira et al. 2009)a n d
of NFAT5 to the S100A4 gene promoter (Chen et al. 2009).
Accordingly, changes in the methylation status of only
several CpGs, as in, for example, the S100B (Namihira et al.
2004) and S100A4 genes (Nakamura et al. 1998), were
reported to bring about a fundamental change in expression.
On the other hand, it was shown that a complete lack of
S100A6 gene expression in HEK293 cells was accompanied
by extensive methylation covering the body of the gene and
its proximal 5′ and 3′ regions (Lesniak et al. 2007). It is thus
probable that not only the differentially methylated cytosine
residues identified in a given study but also additional ones,
located in other non-examined gene regions, may contribute
to the observed differences in S100 protein expression.
An intriguing question that arises with regard to the
clustered organization of the S100 genes is whether
methylation/demethylation events regulating their expression
are local or global. Although the available data on DNA
methylation concern only some S100 genes and only limited
DNA regions have been analyzed, it seems that, no matter
howmanyCpGsshouldbemethylatedtocauseeffective gene
silencing, the region involved does not surpass “the borders”
ofanindividualS100gene.Studies comparingmethylationof
severalS100proteinsinagivencelllineortissueclearlyshow
that genes lying only several kilobases apart differ in
methylation and expression level (Tulchinsky et al. 1992;
Wicki et al. 1997; Elder and Zhao, 2002). Thus, the
conclusion, formulated based on S100A2 and S100A6
methylation/expression in fibroblasts and keratinocytes, that
gene-specific rather than long-range effects on chromatin
structure is decisive in the regulation of S100 gene
expression (Elder and Zhao 2002), seems to apply to the
S100 gene cluster in other tissues as well.
Acknowledgements This work was supported by the statutory funds
of the Nencki Institute of Experimental Biology.
Conflict of interest The author declares no conflict of interests.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S,
Ellison DW, Clifford SC (2008) Global analysis of the
medulloblastoma epigenome identifies disease-subgroup-specific
inactivation of COL1A2. Neuro Oncol 10:981–94. doi:10.1215/
15228517-2008-048
Bird AP, Wolffe AP (1999) Methylation-induced repression—belts,
braces, and chromatin. Cell 99:451–454. doi:10.1016/S0092-
8674(00)81532-9
Chen D, Rudland PS, Chen HL, Barraclough R (1999) Differential
reactivity of the rat S100A4(p9Ka) gene to sodium bisulfite is
associated with differential levels of the S100A4 (p9Ka) mRNA
in rat mammary epithelial cells. J Biol Chem 274:2483–2491.
doi:10.1074/jbc.274.4.2483
Chen M, Sinha M, Luxon BA, Bresnick AR, O'Connor KL (2009) Integrin
alpha6beta4 controls the expression of genes associated with cell
motility, invasion, and metastasis, including S100A4/metastasin. J
Biol Chem 284:1484–1494. doi:10.1074/jbc.M803997200
Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005) Expression of
S100 proteins in normal human tissues and common cancers
using tissue microarrays: S100A6, S100A8, S100A9 and
S100A11 are all overexpressed incommoncancers. Histopathology
46:256–269. doi:10.1111/j.1365-2559.2005.02097.x
Curradi M, Izzo A, Badaracco G, Landsberger N (2002) Molecular
mechanisms of gene silencing mediated by DNA methylation.
M o lC e l lB i o l2 2 : 3 1 5 7 –3173. doi:10.1128/MCB.22.9.3157-
3173.2002
Donato R (2001) S100: a multigenic family of calcium-modulated
proteins of the EF-hand type with intracellular and extracellular
functional roles. Int J Biochem Cell Biol 33:637–668.
doi:10.1016/S1357-2725(01)00046-2
Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE (2008)
Genome-wide analysis in a murine Dnmt1 knockdown model
identifies epigenetically silenced genes in primary human
pituitary tumors. Mol Cancer Res 6:1567–1574. doi:10.1158/
1541-7786.MCR-08-0234
Elder JT, Zhao X (2002) Evidence for local control of gene expression
in the epidermal differentiation complex. Exp Dermatol 11:406–
412. doi:10.1034/j.1600-0625.2002.110503.x
Feng G, Xu X, Youssef EM, Lotan R (2001) Diminished expression of
S100A2, a putative tumor suppressor, at early stage of human
lung carcinogenesis. Cancer Res 61:7999–8004
Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate
genomes. J Mol Biol 196:261–282. doi:10.1016/0022-2836(87)
90689-9
82 Clin Epigenet (2011) 2:77–83Garrett SC, Varney KM, Weber DJ, Bresnick AR (2006) S100A4, a
mediator of metastasis. J Biol Chem 281:677–680. doi:10.1074/
jbc.R500017200
Grigorian MS, Tulchinsky EM, Zain S, Ebralidze AK, Kramerov DA,
Kriajevska MV, Georgiev GP, Lukanidin EM (1993) The mts1
gene and control of tumor metastasis. Gene 135:229–238
Leclerc E, Fritz G, Vetter SW, Heizmann CW (2009) Binding of S100
proteins to RAGE: an update. Biochim Biophys Acta 1793:993–
1007. doi:10.1016/j.bbamcr.2008.11.016
Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R (1992)
Down-regulation of a member of the S100 gene family in
mammary carcinoma cells and reexpression by azadeoxycytidine
treatment. Proc Natl Acad Sci USA 89:2504–2508
Leśniak W, Swart GW, Bloemers HP, Kuźnicki J (2000) Regulation of
cell specific expression of calcyclin (S100A6) in nerve cells and
other tissues. Acta Neurobiol Exp 60:569–575
Leśniak W, Słomnicki ŁP, Kuźnicki J (2007) Epigenetic control of the
S100A6 (calcyclin) gene expression. J Invest Dermatol
127:2307–2314. doi:10.1038/sj.jid.5700879
Li Y, Liu ZL, Zhang KL, Chen XY, Kong QY, Wu ML, Sun Y, Liu J,
Li H (2009) Methylation-associated silencing of S100A4
expression in human epidermal cancers. Exp Dermatol 18:842–
848. doi:10.1111/j.1600-0625.2009.00922.x
Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW,
Clifford SC (2007) Epigenetic deregulation of multiple S100
gene family members by differential hypomethylation and
hypermethylation events in medulloblastoma. Br J Cancer
97:267–274. doi:10.1038/sj.bjc.6603852
Łuczak MW, Jagodziński PP (2006) The role of DNA methylation in
cancer development. Folia Histochem Cytobiol 44:143–154
Malup TK, Kobzev VF, Zhdanova LG, Slobodyanyuk SY, Sviridov
SM (2007) Methylation of CpG dinucleotides in the promoter
region of the gene encoding the S100b protein in BALB/cLac
mice. Dokl Biochem Biophys 412:1–3
Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse
and man: from evolution to function and pathology (including an
update of the nomenclature). Biochem Biophys Res Commun
322:1111–1122. doi:10.1016/j.bbrc.2004.07.096
Marenholz I, Lovering RC, Heizmann CW (2006) The update of the
S100 nomenclature. Biochim Biophys Acta 1763:1282–1283.
doi:10.1016/j.bbamcr.2006.07.013
Nakamura N, Takenaga K (1998) Hypomethylation of the metastasis-
associated S100A4 gene correlates with gene activation in human
colon adenocarcinoma cell lines. Clin Exp Metastasis 16:471–
479. doi:0.1023/A:1006589626307
Namihira M, Nakashima K, Taga T (2004) Developmental stage
dependent regulation of DNA methylation and chromatin
modification in a immature astrocyte specific gene promoter.
FEBS Lett 572:184–188. doi:10.1016/j.febslet.2004.07.029
Namihira M, Kohyama J, Semi K, Sanosaka T, Deneen B, Taga T,
Nakashima K (2009) Committed neuronal precursors confer
astrocytic potential on residual neural precursor cells. Dev Cell
16:245–255. doi:10.1016/j.devcel.2008.12.014
Pedrocchi M, Schäfer BW, Mueller H, Eppenberger U, Heizmann CW
(1994) Expression of Ca(2+)-binding proteins of the S100 family
in malignant human breast-cancer cell lines and biopsy samples.
Int J Cancer 57:684–90
Perera Ch, McNeil HP, Geczy CL (2010) S100 calgranulins in
inflammatory arthritis. Immunol Cell Biol 88:41–49. doi:10.1038/
icb.2009.88
Ravasi T, Hsu K, Goyette J, Schroder K, Yang Z, Rahimi F, Miranda
LP, Alewood PF, Hume DA, Geczy C (2004) Probing the S100
protein family through genomic and functional analysis.
Genomics 84:10–22. doi:10.1016/j.ygeno.2004.02.002
Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S,
Champigneuille J, Fromont G, Cussenot O, Hamdy FC (2004)
S100A6 (Calcyclin) is a prostate basal cell marker absent in
prostate cancer and its precursors. Br J Cancer 91:739–44.
doi:10.1038/sj.bjc.6602034
Rehman I, Cross SS, Catto JW, Leiblich A, Mukherjee A, Azzouzi
AR, Leung HY, Hamdy FC (2005) Promoter hyper-methylation
of calcium binding proteins S100A6 and S100A2 in human
prostate cancer. Prostate 65:322–330. doi:10.1002/pros.20302
Ridinger K, Ilg EC, Niggli FK, Heizmann CW, Schäfer BW (1998)
Clustered organization of S100 genes in human and mouse.
Biochim Biophys Acta 1448:254–263. doi:10.1016/S0167-4889
(98)00137-2
Rosty C, Ueki T, Argani P, Jansen M, Yeo CJ, Cameron JL, Hruban
RH, Goggins M (2002) Overexpression of S100A4 in pancreatic
ductal adenocarcinomas is associated with poor differentiation
and DNA hypomethylation. Am J Pathol 160:45–50
Salama I, Malone PS, Mihaimeed F, Jones JL (2008) A review of the
S100 proteins in cancer. Eur J Surg Oncol 34:357–364.
doi:10.1016/j.ejso.2007.04.009
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-
dependent and -independent interactions of the S100 protein
family. Biochem J 396:201–214. doi:10.1042/BJ20060195
SatoN,FukushimaN,Matsubayashi H, Goggins M(2004)Identification
ofmaspinandS100Pasnovelhypomethylationtargetsinpancreatic
cancer using global gene expression profiling. Oncogene 23:1531–
1538. doi:10.1038/sj.onc.1207269
Schäfer BW, Wicki R, Engelkamp D, Mattei MG, Heizmann CW
(1995) Isolation of a YAC clone covering a cluster of nine S100
genes on human chromosome 1q21: rationale for a new
nomenclature of the S100 calcium-binding protein family.
Genomics 25:638–643
Sedaghat F, Notopoulos A (2008) S100 protein family and its
application in clinical practice. Hippokratia 12:198–204
Shang X, Cheng H, Zhou R (2008) Chromosomal mapping,
differential origin and evolution of the S100 gene family. Genet
Sel Evol 40:449–464. doi:10.1051/gse:2008013
Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in
human chromosomes 21 and 22. Proc Natl Acad Sci USA
99:3740–3745. doi:10.1073/pnas.052410099
Tulchinsky E, Ford HL, Kramerov D, Reshetnyak E, Grigorian M,
Zain S, Lukanidin E (1992) Transcriptional analysis of the mts1
gene with specific reference to 5' flanking sequences. Proc Natl
Acad Sci USA 89:9146–9150
Tulchinsky E, Grigorian M, Tkatch T, Georgiev G, Lukanidin E
(1995) Transcriptional regulation of the mts1 gene in human
lymphoma cells: the role of DNA-methylation. Biochim Biophys
Acta 1261:243–248. doi:10.1016/0167-4781(95)00013-7
Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A,
Nariculam J, Hubank MJ, Ahmed A, Masters JR (2007)
Hypomethylation of WNT5A, CRIP1 and S100P in prostate
cancer. Oncogene 26:6560–6565. doi:10.1038/sj.onc.1210472
Wang XH, Zhang LH, Zhong XY, Xing XF, Liu YQ, Niu ZJ, Peng Y,
Du H, Zhang GG, Hu Y, Liu N, Zhu YB, Ge SH, Zhao W, Lu
AP, Li JY, Ji JF (2010) S100A6 overexpression is associated with
poor prognosis and is epigenetically up-regulated in gastric
cancer. Am J Pathol 177:586–597
Wicki R, Franz C, Scholl FA, Heizmann CW, Schäfer BW (1997)
Repression of the candidate tumor suppressor gene S100A2 in
breast cancer is mediated by site-specific hypermethylation. Cell
Calcium 22:243–254. doi:10.1016/S0143-4160(97)90063-4
Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR
(2007) Hypomethylation-induced expression of S100A4 in
endometrial carcinoma. Mod Pathol 20:1045–54. doi:10.1038/
modpathol.3800940
Zhang X, Hunt JL, Shin DM, Chen ZG (2007) Down-regulation of
S100A2 in lymph node metastases of head and neck cancer.
Head Neck 29:236–243. doi:10.1002/hed.20511
Clin Epigenet (2011) 2:77–83 83